Qiagen N.V. (QGEN) Receives “Overweight” Rating from Barclays PLC

Qiagen N.V. (NASDAQ:QGEN)‘s stock had its “overweight” rating reiterated by Barclays PLC in a research report issued to clients and investors on Monday, July 17th. They presently have a $37.00 price objective on the stock, up from their prior price objective of $33.00. Barclays PLC’s target price would suggest a potential upside of 17.50% from the company’s previous close.

A number of other analysts also recently weighed in on QGEN. TheStreet raised shares of Qiagen N.V. from a “c” rating to a “b” rating in a research report on Monday, June 5th. Zacks Investment Research raised shares of Qiagen N.V. from a “sell” rating to a “hold” rating in a research report on Friday, April 21st. Commerzbank Ag reaffirmed a “buy” rating on shares of Qiagen N.V. in a research report on Monday, May 29th. DZ Bank AG reaffirmed a “neutral” rating on shares of Qiagen N.V. in a research report on Monday, May 29th. Finally, BidaskClub downgraded shares of Qiagen N.V. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 10th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $33.19.

Qiagen N.V. (NASDAQ:QGEN) opened at 31.49 on Monday. The firm has a 50-day moving average of $33.39 and a 200-day moving average of $31.16. The company has a market cap of $7.19 billion, a price-to-earnings ratio of 96.30 and a beta of 1.14. Qiagen N.V. has a 52 week low of $24.89 and a 52 week high of $35.26.

Qiagen N.V. (NASDAQ:QGEN) last released its earnings results on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.02. The business had revenue of $349 million during the quarter, compared to the consensus estimate of $353.09 million. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.24 EPS. Equities analysts forecast that Qiagen N.V. will post $1.23 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.com-unik.info/2017/08/12/qiagen-n-v-s-qgen-overweight-rating-reiterated-at-barclays-plc-updated-updated-updated.html.

A number of hedge funds have recently bought and sold shares of QGEN. Ontario Teachers Pension Plan Board acquired a new stake in Qiagen N.V. during the second quarter valued at about $469,000. OxFORD Asset Management LLP increased its stake in Qiagen N.V. by 25.6% in the second quarter. OxFORD Asset Management LLP now owns 76,100 shares of the company’s stock valued at $2,552,000 after buying an additional 15,521 shares during the last quarter. Virtu KCG Holdings LLC increased its stake in Qiagen N.V. by 59.0% in the second quarter. Virtu KCG Holdings LLC now owns 11,267 shares of the company’s stock valued at $378,000 after buying an additional 4,179 shares during the last quarter. Renaissance Technologies LLC increased its stake in Qiagen N.V. by 4.8% in the second quarter. Renaissance Technologies LLC now owns 1,588,208 shares of the company’s stock valued at $53,253,000 after buying an additional 73,310 shares during the last quarter. Finally, Ramsey Quantitative Systems acquired a new stake in Qiagen N.V. during the second quarter valued at about $354,000. 59.84% of the stock is owned by institutional investors and hedge funds.

Qiagen N.V. Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen N.V. (NASDAQ:QGEN)

What are top analysts saying about Qiagen N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Qiagen N.V. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit